Mutations in the JAK-STAT pathway occur frequently, especially JAK3 mutations, which have been reported in 21-42% of T-PLL, suggesting that T-PLL patients could benefit from JAK inhibitors, mostly JAK3 inhibitors. Here, JAK3 is linked to prolymphocytic leukemia.